Recent studies suggest that nuclear factor jB-inducing kinase (NIK) is suppressed through constitutive proteasome-mediated degradation regulated by TRAF2, TRAF3 and cIAP1 or cIAP2. Here we demonstrated that the degradation of NIK occurs upon assembly of a regulatory complex through TRAF3 recruitment of NIK and TRAF2 recruitment of cIAP1 and cIAP2. In contrast to TRAF2 and TRAF3, cIAP1 and cIAP2 seem to play redundant roles in the degradation of NIK, as inhibition of both cIAPs was required for noncanonical NF-jB activation and increased survival and proliferation of primary B lymphocytes. Furthermore, the lethality of TRAF3 deficiency in mice could be rescued by a single NIK gene, highlighting the importance of tightly regulated NIK.
The Rel-NF-kB family of transcription factors affects many biological processes, including bone homeostasis, cellular proliferation and apoptosis, the initiation and propagation of innate and adaptive immune responses, and the development of secondary lymphoid tissue architecture [1] [2] [3] . Research in recent years has defined two distinct NF-kB (A002937) activation pathways, termed the canonical and noncanonical NF-kB pathways 4 . Briefly, the canonical NF-kB pathway, activated by most stress stimuli, results in IkB kinase (IKK) complex-mediated degradation of IkB and rapid nuclear accumulation of p50-RelA and p50-cRel NF-kB complexes 5 . In contrast, activation of the noncanonical NF-kB pathway by a select group of tumor necrosis factor (TNF) receptors such as CD40 (ref. 6 ), lymphotoxin-b receptor (LTbR) 7 and BAFF receptor (BAFF-R) 7 results in slow processing of the C terminus of p100 to produce p52 and kinetically slower nuclear translocation of the p52-RelB NF-kB complex 8 .
In contrast to receptor-mediated activation of the canonical NF-kB pathway, which occurs within minutes and does not require new protein synthesis, activation of the noncanonical NF-kB pathway takes several hours and requires new protein synthesis. Notably, activation of the noncanonical NF-kB pathway requires NIK [9] [10] [11] (A001654). Evidence suggests that NIK protein is suppressed by direct interaction with TRAF3 (A002309; ref. 12 ), a member of the tumor necrosis factor receptor associated factor (TRAF) family, which includes TRAFs 1-6. In support of this concept, TRAF3-deficient cells show constitutive processing of p100 to p52 processing as a result of accumulated NIK 13 .
In addition, a recent report demonstrated spontaneous p100-to-p52 processing in mice with a conditional disruption of the gene for TRAF2 (A002308) in B lymphocytes 14 , suggesting that TRAF2 also functions as an essential negative regulator of the noncanonical NF-kB pathway.
A recent characterization of primary multiple myelomas showing high NIK levels and constitutive p100-to-p52 processing identified several classes of chromosomal alterations. These included NIK amplifications as well as TRAF2 or TRAF3 chromosomal deletions 15, 16 . Notably, these analyses also identified a subset of samples showing dual chromosomal loss of cellular inhibitor of apoptosis 1 and 2 (cIAP1 and cIAP2), suggesting that cIAP1 and cIAP2 are also involved in the negative regulation of NIK. Coincidently, development of pharmacological inhibitors of cIAPs has been a major goal in advancing cancer therapeutics, as cIAPs are believed to antagonize activated caspases and are often amplified in human cancers 17, 18 . Recent studies characterizing several newly developed inhibitors of cIAPs found that global inhibition of cIAPs activated the noncanonical NF-kB pathway in a NIK-dependent manner 19, 20 and that overexpression of cIAP1 could target NIK for ubiquitination and degradation. Notably, neither cIAP1-nor cIAP2-deficient mice show the perinatal death seen in TRAF3-deficient mice, indicating that the absence of either cIAP1 or cIAP2 is insufficient to affect the regulation of NIK 21, 22 . However, how TRAF2 and TRAF3 cooperate with cIAP1 and/or cIAP2 in the proteasomal targeting of NIK remains to be defined.
In this report, we provide evidence that TRAF2 and TRAF3 play distinct roles in recruiting cIAP1 and cIAP2 to a regulatory complex that promotes degradation of NIK and suppression of the noncanonical NF-kB pathway. In contrast to previous reports showing cell death induced by pharmacological inhibitors of IAPs, we found that the same IAP inhibitors substantially enhanced B lymphocyte survival and proliferation through activation of the noncanonical NF-kB pathway. Collectively, these data provide insight into the assembly of the NIK regulatory complex and bring to light potential immunological hazards of IAP inhibition for the treatment of cancer.
RESULTS

TRAF2 and TRAF3 perform nonredundant functions
Although recent studies indicate that TRAF2, TRAF3, cIAP1 and cIAP2 all function as negative regulators of noncanonical NF-kB activation, the molecular mechanisms by which each of these control basal NIK levels or NIK levels upon TNF receptor activation remain to be elucidated. In particular, little is known about functional specificity between TRAF2 and TRAF3, even though mice lacking either TRAF2 or TRAF3 die within 2 weeks of birth with constitutively activated noncanonical NF-kB. To directly compare the abilities of TRAF2 and TRAF3 to negatively regulate noncanonical NF-kB, Flag-TRAF2 or Flag-TRAF3 was stably expressed in TRAF3-deficient (Traf3 -/-) and TRAF2-deficient (Traf2 -/-) mouse embryonic fibroblasts (MEFs). Immunoblot analysis of NIK and p100-to-p52 processing showed that even when expressed at equivalent levels, TRAF2 was not able to compensate for the spontaneous accumulation of NIK and p100-to-p52 processing resulting from the loss of TRAF3 ( Fig. 1a , left panel). Likewise, TRAF3 was not able to compensate for spontaneous noncanonical activation of NF-kB resulting from loss of TRAF2 ( Fig. 1a , right panel), indicating that TRAF2 and TRAF3 perform specific functions in negatively regulating noncanonical NF-kB activation. cIAP1 and cIAP2 perform redundant functions Understanding potential functional redundancy of cIAP1 and cIAP2 has been impeded because of their chromosomal proximity, which prevents the generation of mice with targeted disruption of both molecules. To determine whether cIAP1 and cIAP2 perform redundant roles in the negative regulation of NIK, we introduced small interfering RNAs (siRNA) against cIAP1, cIAP2 or both into wild-type MEFs, cIAP2-specific siRNA into cIAP1-deficient (Birc2 -/-) MEFs and cIAP1-specific siRNA into cIAP2-deficient (Birc3 -/-) MEFs. We then assessed activation of NIK by immunoblot analysis of p100-to-p52 processing ( Fig. 1b) . We found that treatment of wild-type cells with siRNA specific for either cIAP1 or cIAP2 had a negligible effect on p100-to-p52 processing; in contrast, treatment with both cIAP1specific and cIAP2-specific siRNAs resulted in an increased in p52 levels. Moreover, whereas in wild-type cells treatment with either cIAP2-specific or cIAP1-specific siRNA alone did not induce p100-to-52 processing, in cIAP1-deficient and cIAP2-deficient MEFs treatment with cIAP2-specific and cIAP1-specific siRNA alone, respectively, did activate p100-to-p52 processing. Similar results were obtained in primary hepatocytes (Fig. 1c) . These data strongly suggested that cIAP1 and cIAP2 functioned redundantly in the degradation of NIK. We hypothesized that this function was by means of cIAP ubiquitination of NIK. To verify this hypothesis, we transfected human embryonic kidney (HEK) 293T cells with NIK and ubiquitin in the absence or presence of cIAP1 or cIAP2. Both cIAP1 and cIAP2 (cIAPs) promoted ubiquitination of NIK, whereas their RING domain deletion mutants cIAP1D and cIAP2D, lacking E3 ligase activity, did not ( Supplementary Fig. 1a online). We also definitively verified NIK ubiquitination by cIAPs through immunoprecipitation of ubiquitin followed by immunoblot analysis of NIK ( Supplementary  Fig. 1b ). We therefore concluded that cIAPs perform redundant roles as ubiquitin ligases in the negative regulation of NIK and noncanonical NF-kB activation.
TRAF2 and TRAF3 promote cIAP association with NIK Genetic data provide strong evidence for a complex that regulates NIK, consisting of TRAF2, TRAF3, cIAP1, cIAP2 and NIK. To test this model, we treated primary B lymphocytes with the proteasome inhibitor MG132 to allow NIK accumulation. Here, immunoprecipitation of NIK resulted in the coimmunoprecipitation of TRAF2, TRAF3 and cIAPs ( Fig. 2a) . Similar results were also obtained in MEFs ( Supplementary Fig. 2 online) . These analyses verified the proposed NIK regulatory complex. We next wanted to determine whether TRAF2 and TRAF3 bind to NIK independently of one another, cooperatively, or coordinatedly. Here, we introduced pBABE-Flag-NIK into NIK-deficient (Map3k14 -/-), Traf3 -/-, and Traf2 -/-MEFs. Flag immunoprecipitates were then analyzed by immunoblot. This analysis demonstrated that TRAF2 was not required for the association of NIK with TRAF3 ( Fig. 2b) . In contrast, TRAF2 binding to NIK required TRAF3 ( Fig. 2c) . Thus, TRAF3 binds NIK independently, serving to coordinate the recruitment of TRAF2 to the NIK regulatory complex. Notably, association of cIAPs with NIK was also lost in the absence of TRAF3 ( Fig. 2d) . Similar results were also obtained in BCR-Abl transformed wild-type and Traf3 -/-B cell lines ( Fig. 2e) . These results led us to speculate that TRAF2 might mediate the recruitment of cIAPs to NIK through TRAF3. To explore (a) Immunoblot of lysates of wild-type (WT) and Traf3 À/À (left panel) or WT and Traf2 À/À (right panel) MEFs reconstituted with empty pBABE-Flag vector (EV), pBABE-Flag-TRAF2 (T2) and pBABE-Flag-TRAF3 (T3). Noncanonical NF-kB activation was assessed by immunoblot analysis of NIK and p100-to-p52 processing. (b) Immunoblot of WT, Birc2 À/À and Birc3 À/À MEFs transiently transfected with nontargeting (NT) siRNA or cIAP1-specific and/or cIAP2-specific siRNA as indicated at top. Activation of the noncanonical NF-kB pathway was then assessed by analysis of p100-to-p52 processing 24 h after transfection. (c) Immunoblot of WT and Birc2 À/À primary hepatocytes transiently transfected with NT, cIAP1-specific and/or cIAP2-specific siRNA as indicated at top. Activation of the noncanonical NF-kB pathway was then assessed by analysis of p100-to-p52 processing 24 h after transfection. Results are representative of at least three independent experiments.
this, we generated wild-type and Traf2 -/-3T3 cell lines expressing pBABE-Flag-cIAP1 or pBABE-Flag-cIAP2. Flag immunoprecipitates were then analyzed by immunoblot ( Fig. 2f ). Here, we detected association of both cIAPs with TRAF2 and TRAF3 in the wild-type cell lines. We also found that the interaction between TRAF3 and cIAPs was lost in the Traf2 -/cells indicating that TRAF2 is required for TRAF3-cIAPs interaction. We therefore suggest that cIAPs are recruited to the TRAF3-NIK complex through TRAF2.
TRAF2 and TRAF3 affinities for cIAPs and NIK
The finding that TRAF2 interaction with NIK required TRAF3 was unexpected, as NIK was first identified as a TRAF2-interacting protein by yeast-two hybrid assay 23 . To gain further insight, we directly compared the binding affinities of TRAF2 and TRAF3 for NIK in HEK 293T cells. This analysis revealed that TRAF3 bound NIK with much higher affinity than TRAF2 ( Fig. 3a ). In addition, siRNAmediated knockdown of endogenous TRAF3 in HEK 293T cells markedly reduced TRAF2 interaction with NIK (Supplementary Fig. 3 online) . These data strongly suggest that TRAF2 is unable to bind NIK under endogenous conditions, explaining the requirement of TRAF3 for TRAF2-NIK interaction (Fig. 2c) . In contrast, TRAF2 has long been known to functionally associate with cIAP1 and cIAP2 (ref. 24) . No data regarding TRAF3 interaction with cIAP1 or cIAP2 has yet been reported. Therefore, we next compared the binding affinities of TRAF2 and TRAF3 for cIAP1 and cIAP2 in HEK 293T cells. When TRAF2 and TRAF3 were expressed at low levels, we observed only TRAF2, not TRAF3, in association with both cIAP1 and cIAP2 ( Fig. 3b ). When the expression of TRAF3 in similar experiments was increased in titration studies, we were able to detect TRAF3 association with cIAP2 but not cIAP1. However, the interaction of cIAP2 with TRAF3 was always weaker than the interaction with TRAF2 ( Supplementary Fig. 4a ,b online). These data strongly suggest that TRAF3 is unable to bind to either cIAP1 or cIAP2 under endogenous conditions, explaining the requirement of TRAF2 for Figure 2 Assembly of the NIK regulatory complex by TRAF2 and TRAF3. (a) Immunoassays on lysates of primary mouse B cells treated with the proteasomal inhibitor MG132 for 4 h and then incubated with rabbit IgG or anti-NIK. Protein complexes were then immunoprecipitated (IP) with protein G beads followed by the immunoblot analysis indicated at right. (b) Immunoassays on lysates of Map3k14 À/À , Traf3 À/À and Traf2 À/À MEFs reconstituted with empty pBABE-Flag vector (EV) or pBABE-Flag-NIK (NIK). Complexes were immunoprecipitated with anti-Flag M2 beads, followed by the immunoblot indicated at right. (c,d) Immunoassays on lysates from Map3k14 À/À and Traf3 À/À MEFs reconstituted with EV or NIK incubated with anti-Flag M2 beads. Complexes were immunoprecipitated, followed by the immunoblot analysis indicated at right. (e) Immunoassays on lysates from MG132-treated, BCR-Abl transformed wild-type (WT) and Traf3 À/À B cell lines incubated with control rabbit IgG or anti-NIK followed by protein G beads. Complexes were immunoprecipitated, followed by the immunoblot analysis indicated at right. (f) Immunoassays on lysates from WT and Traf2 À/À 3T3 cells reconstituted with pBABE-Flag-cIAP1, pBABE-Flag-cIAP2 or empty vector (EV) control. Cell lysates were then immunoprecipitated with anti-Flag M2 beads and coimmunoprecipitation of TRAF2 and TRAF3 was detected by immunoblot. Data are representative of at least three experiments.
IP: Flag
Lysate interaction between TRAF3 and the cIAPs ( Fig. 2e) . Taken together, we conclude that the nonredundant functions of TRAF2 and TRAF3 in the negative regulation of the noncanonical NF-kB pathway result from their differential high-affinity associations with the cIAPs and NIK, respectively.
Previous work has shown dynamic interactions between TRAF2 and TRAF3 in living cells 25 . Given this, and the striking differential affinities of TRAF2 and TRAF3 for the cIAPs and NIK, we propose an uncomplicated model to explain the nonredundant roles of TRAF2 and TRAF3 in the negative regulation of NIK: specifically, direct interaction between TRAF2 and TRAF3 functions as a bridge between the cIAPs and NIK ( Supplementary Fig. 5 online) . To verify this model, we sought to reproduce the NIK regulatory complex in HEK 293T cells. Here, co-expression of NIK with either cIAP1 or cIAP2 alone resulted in no interaction between NIK and cIAPs. Likewise, the additional expression of TRAF2 or TRAF3 alone did not mediate any interaction between the cIAPs and NIK. In contrast, simultaneous expression of TRAF2 and TRAF3 resulted in the assembly of a NIK-cIAPs complex (Fig. 3c) . These data provide strong support for a model in which TRAF2 and TRAF3 cooperate in the negative regulation of NIK by 'bridging the gap' between the cIAPs and NIK.
A chimeric TRAF2-TRAF3 protein
The study of TRAF family members has been enhanced by chimeric strategies that have elucidated the sequence specificity of TRAF family members with biochemical pathway activation potential [26] [27] [28] . Given the previous success of this strategy, we generated several TRAF2-TRAF3 chimeras, two of which are shown in Supplementary Figure 6 online. Using the pBABE-Flag retroviral system, we introduced TRAF3, 3TD (consisting of the TRAF3 TRAF domain and the RING and zinc finger domains of TRAF2), TRAF2 and 2TD (consisting of the TRAF2 TRAF domain and the RING and zinc finger domains of TRAF3) into Traf3 -/-MEFs and then analyzed p100-to-p52 processing by immunoblot ( Fig. 4a ). As expected, expression of TRAF3, but not TRAF2, in Traf3 -/-MEFs restored p100-to-p52 processing to normal basal levels. In addition, 3TD, but not 2TD, in Traf3 À/À MEFs restored p100-to-p52 processing to normal basal levels. These data demonstrate that the TRAF domain of TRAF3 provides a unique function in the negative regulation of NIK. Notably, the ability of 3TD to prevent constitutive processing of p100 to p52 in Traf3 -/cells was not affected by siRNA-mediated knockdown of TRAF2 ( Supplementary Fig. 7 online). Next, identical experiments were performed in Traf2 -/-MEFs (Fig. 4b) . As expected, expression of TRAF2, but not TRAF3, in Traf2 -/-MEFs restored p100-to-p52 processing to normal levels. Of particular note, as seen in Traf3 -/cells, 3TD but not 2TD also restored p100-to-p52 processing to normal basal levels. Thus, the RING domain and zinc fingers of TRAF2 also provide a protein-targeting function crucial for the negative regulation of NIK. Taken together, these data suggest that the 3TD chimera unites the nonredundant roles of TRAF2 and TRAF3 into a single molecule.
To further characterize the 3TD chimera, we compared the binding affinity of these TRAF constructs for NIK in HEK 293T cells. As expected, TRAF2 interacted much more weakly with NIK than did TRAF3 (Fig. 5a ). Construct 3TD, but not 2TD, interacted with NIK as strongly as TRAF3. Thus, the TRAF domain of TRAF3 mediated highaffinity binding to NIK. We next compared the binding affinities of the TRAF constructs for cIAP1 and cIAP2. As expected, TRAF2, but not TRAF3, interacted with cIAP1 and cIAP2 (Fig. 5b) . The 3TD construct, but not 2TD, interacted with both cIAP1 and cIAP2. These findings suggest that the ability of the 3TD chimera to rescue proper regulation of NIK in both Traf2 -/and Traf3 -/cells resulted from uniting the individual binding capacities of TRAF2 and TRAF3 for the cIAPs and NIK into a single molecule.
Given the ability of the 3TD chimera to bind both cIAPs and NIK with high affinity, we would predict that this molecule should obviate the requirement for both TRAF2 and TRAF3 in promoting formation of a NIK-cIAPs complex. To test this model, NIK and Myc-cIAP1 together were expressed alone or in the presence of the TRAF constructs in HEK 293T cells. Here, no interaction between cIAP1 and NIK was detected in the absence of exogenous TRAF expression ( Fig. 5c ). In addition, whereas TRAF2, TRAF3 and 2TD did not lead to a significant interaction between cIAP1 and NIK, 3TD promoted a strong association. Identical experiments were also performed with cIAP2 ( Fig. 5d) . Here, only 3TD was able to promote robust interaction of cIAP2 with NIK over the background control.
Collectively, these data demonstrate that the 3TD chimera is more efficient at promoting a NIK-cIAPs complex than either TRAF2 or TRAF3 alone.
TRAF2 and TRAF3 degradation prevents cIAPs-NIK association
At present, a model explaining the mechanism of receptor-induced activation of the noncanonical NF-kB activation pathway has not been provided. Various groups have shown receptor induced degradation of TRAF2 upon CD40 engagement 12, [29] [30] [31] . Notably, we found that treatment of the A20 B cell line and of primary mouse B lymphocytes with agonistic antibody to CD40 (anti-CD40; FgK-45) induced both TRAF2 and TRAF3 degradation, with kinetics similar to those of activation of the noncanonical NF-kB pathway (Fig. 6a,b ). In both cell types, degradation of TRAF3 preceded more rapidly than degradation of TRAF2, suggesting that degradation of TRAF3 initiates NIK-cIAPs disassociation. Additionally, CD40-induced degradation of TRAF2 and TRAF3 was inhibited by a small-molecule mimetic ('SMAC mimetic') of the proapoptotic protein SMAC (second mitochondria-derived activator of caspases), which inhibits cIAPs 32 . These data suggest that TRAF3-binding receptors stabilize NIK by activating cIAP-dependent degradation of TRAF2 and TRAF3. To test this model further, we first introduced CD40L and CD40 to the NIK regulatory complex assay in HEK 293T cells (see Fig. 3d ). We found that engagement of CD40 prevented the ability of TRAF2 and TRAF3 to coordinate assembly of the NIK-cIAPs complex ( Supplementary Fig. 8 online) . In addition, we also analyzed the NIK regulatory complex in the A20 B cell line before and after ligation of CD40 (Fig. 6c ). Ligation of CD40, but not MG132 treatment, prevented the association between cIAPs and NIK. These data demonstrate that stabilization of NIK by TRAF3-binding receptors results from degradation of TRAF2 and TRAF3, thereby preventing cIAP-mediated ubiquitination and degradation of NIK.
SMAC-mimetic compounds mimic BAFF stimulation
Recently, two reports used two different second generation SMAC mimetic compounds to show that inhibition of cIAPs can activate NF-kB noncanonically 19, 20 . Taking advantage of these compounds, we treated wild-type, Traf3 -/and Map3k14 -/-MEF cells with SMAC mimetic. As expected, SMAC mimetic induced p100 processing in wild-type but not Map3k14 -/cells, whereas it did not further enhance the constitutively activated p100 processing in Traf3 -/-MEFs (Fig. 7a,b) . To examine the effects of cIAP inhibition on B cells, we treated primary B lymphocytes with either SMAC mimetic or known activators of the noncanonical NF-kB pathway (BAFF or anti-CD40) for 12 h. Consistent with the results in the MEF cells, SMAC mimetic treatment of primary B cells induced p100-to-p52 processing, to a degree similar to that elicited by BAFF or anti-CD40 ( Fig. 7c) . We next compared the abilities of BAFF, SMAC mimetic and the second generation SMAC mimetic LBW242 to protect B cells from undergoing spontaneous apoptosis during in vitro culture (Fig. 7d) .
We found that either SMAC mimetic or LBW242 elicited a frequency of B lymphocyte survival similar to that elicited by BAFF, indicating, in contrast to their ability to potentiate cell death in many cancer lines, a proapoptotic function for cIAPs in B lymphocytes. Co-stimulation of B lymphocytes with Toll-Like Receptor (TLR) ligands and BAFF results in robust augmentation of B lymphocyte proliferation 33 . To explore the role of cIAPs in B lymphocyte proliferation, we examined whether SMAC-mimetic compounds could 'mimic' BAFF-mediated enhancement of B cell proliferation in response to TLR ligation. B cells were treated with incremental concentrations of the TLR9 ligand CpG in the presence or absence of BAFF or LBW242, and then proliferation was assessed (Fig. 7e) . As expected, co-stimulation of B lymphocytes with BAFF significantly augmented proliferative responses elicited by CpG; similarly, LBW242 also markedly augmented proliferative responses elicited by CpG. These data demonstrate that cIAPs have an antiproliferative function in B lymphocytes.
Rescue of TRAF3-deficiency by a single NIK gene
As a critical kinase involved in noncanonical NF-kB activation, NIK is not detectable in the basal state of most cell types and can only be induced by a select group of receptors such as BAFF-R, CD40 and LTbR. Elevated NIK expression resulting from Map3k14 gene amplification or mutations of the NIK-binding site on TRAF3 has recently been implicated in the development of human multiple myeloma. These data indicate the importance of tight control of NIK levels. This necessity is problematic for the potential use of SMAC-mimetic compounds in cancer therapy regimes owing to potential undesirable effects resulting from NIK activation. We have previously shown that all Traf3 -/mice die within 2 weeks of birth and that Traf3 -/cells have elevated NIK expression and constitutive noncanonical NF-kB activation. We have also shown that deletion the NF-kB p100 gene (Nfkb2) rescued the TRAF3-null phenotype 13 . We have now generated Traf3 -/-Map3k14 -/mice, which, as expected, rescued the TRAF3-null phenotype (Fig. 8a) . In addition, where Traf3 -/mice show severe depletion of all lymphocyte lineages, Traf3 -/-Map3k14 -/mice produce lymphocyte populations similar to those observed in Map3k14 -/mice ( Supplementary Fig. 9a online) . Unexpectedly, however, whereas Traf3 -/mice heterozygous at the p100 gene survive only a few days longer than Traf3 -/mice, Traf3 -/-Map3k14 +/mice can survive for months after birth, though these mice do show a significant reduction in body mass (Fig. 8b) . It was recently reported that endogenous accumulation of NIK markedly amplifies activation of the canonical NF-kB pathway and gene induction through the IKK complex 34 . Indeed, we found that the inflammatory gene target Cxcl10 (the gene for IP-10), which is elevated in Traf3 -/tissues, is expressed at wild-type levels in the tissues of Traf3 -/-Map3k14 -/mice ( Supplementary  Fig. 9b ). One potential difference between the Traf3 -/-Nfkb2 +/and Traf3 -/-Map3k14 +/survival curves could be the degree of canonical NF-kB amplification resulting from accumulated NIK, as the Traf3 -/-Nfkb2 +/still have two alleles of NIK. To determine the contribution of the canonical NF-kB pathway to the TRAF3-null phenotype, we crossed Traf3 +/mice to mice deficient for the p105-p50 gene (Nfkb1). Deletion of p50 is very effective in disrupting pathological responses associated with hyperactive canonical NF-kB activity, as evidenced by the partial rescue of the IkBa-deficient (Nfkbib -/-) phenotype by simultaneous deletion of Nfkb1 (ref. 35 ). Analysis of Traf3 -/-Nfkb1 -/mice, however, revealed no impact on the postnatal lethality or elevated serum corticosterone resulting from loss of TRAF3 (Fig. 8c,d) . This finding suggests that NIK levels may be insufficient to induce robust p100-to-p52 processing in Traf3 -/-Map3k14 +/mice.
DISCUSSION
Activation of the noncanonical NF-kB pathway by NIK is essential for the organization of secondary lymphoid tissue, whereas deregulation of this pathway results in several human diseases, including cancers.
Although genetic studies indicate that TRAF2, TRAF3, cIAP1 and cIAP2 are all involved in the negative regulation of the noncanonical NF-kB pathway, little is known about the biochemical mechanisms responsible for regulation of NIK amounts before and after receptor activation. In this study, we elucidate a simple model showing the distinct roles of TRAF2 and TRAF3 in bridging the gap between the cIAPs and NIK to form a complex to promote NIK degradation. In addition, we explored the potential of SMAC-mimetic compounds to mimic BAFF-like co-stimulation of B lymphocytes. Notably, we found that such IAP antagonists greatly augmented B lymphocyte survival and proliferation. Collectively, these data advance our mechanistic understanding of the NIK regulatory complex and reveal potential complications in therapeutic application of SMACmimetic compounds. At present, it is clear that basal activity of the noncanonical NF-kB pathway is suppressed by constitutive suppression of NIK protein levels through direct interaction with TRAF3 (refs. 12, 13, 15) . Recent genetic and pharmacological studies further suggest that TRAF2 and the cIAPs cooperate with TRAF3 in the proteasomal targeting of NIK, but a potential mechanism has not been described 12, 13, 15, 16, 19, 20, 36 . We found that overexpression of either TRAF2 or TRAF3 in Traf3 -/or Traf2 -/cells, respectively, could not compensate for the loss of the other. These results strongly suggest that both TRAF2 and TRAF3 possess specific and unique functions in the basal suppression of NIK. A comparison of the binding of TRAF2 and TRAF3 to the cIAPs and NIK revealed markedly different abilities, with TRAF2 binding both cIAP1 and cIAP2 strongly and TRAF3 binding NIK strongly. With this finding, and the knowledge that TRAF2 and TRAF3 can heterodimerize in living cells 25 , we reasoned that TRAF2 and TRAF3 might function as a bridge to couple cIAPs with NIK. We further identified a chimeric 3TD, containing the zinc RING and zinc finger domains of TRAF2 and the TRAF domain of TRAF3, that promoted cIAPs interaction with NIK more efficiently than either TRAF2 or TRAF3 alone. Notably, this 3TD chimera is able to suppress the high basal noncanonical NF-kB activities of both Traf3 -/and Traf2 -/cells, which supports our proposed model.
In addition to similar results in previous reports that TRAF2 and TRAF3 are degraded after receptor activation 12, [29] [30] [31] 36, 37 , our studies further demonstrated that SMAC mimetic compounds could strongly inhibit receptor-induced TRAF2 and TRAF3 degradation, suggesting that cIAPs are required for their degradation. In our model, degradation of either TRAF2 or TRAF3 is sufficient to cause the dissociation of the NIK-cIAPs complex, resulting in accumulation of NIK through new protein synthesis. This also agrees with previous reports showing that BAFF-R, CD40 or LTbR-mediated noncanonical NF-kB requires new protein synthesis.
Whereas TRAF2 and TRAF3 play distinct roles, our studies indicate that cIAP1 and cIAP2 are redundant in the negative regulation of noncanonical NF-kB activation. We have shown that either cIAP1 or cIAP2 can be recruited to the NIK complex through TRAF2 and TRAF3. More importantly, knockdown of cIAP1 in Birc3 -/cells, knockdown of cIAP2 in Birc2 -/cells or knockdown of both in wildtype cells results in NIK accumulation and noncanonical NF-kB activation. Consistently with recently studies, SMAC-mimetic compounds, which strongly inhibit both cIAP1 and cIAP2, lead to NIK accumulation and noncanonical NF-kB activation. However, whereas those studies showed that SMAC mimetic compounds can potentiate cell death in certain cancer cell lines 20, 38 , our study has shown that the same SMAC mimetic compounds can actually promote the survival and proliferation of primary B lymphocytes owing to the induction of the noncanonical NF-kB pathway.
The present work further demonstrates that disruption of a single allele of the NIK gene is sufficient to rescue the TRAF3-null lethal phenotype, suggesting that NIK levels need to be tightly and precisely regulated. Elegant work recently 15, 16 found that a subgroup of multiple myeloma cells expresses elevated noncanonical NF-kB activity owing to Map3k14 amplification, Traf3 mutation or loss of expression of both Birc2 and Birc3 genes. These results fit well with our proposed model, in which nonredundant TRAFs cooperate with redundant cIAPs in negative regulation of NIK and noncanonical NF-kB activity. Finally, given the known dangers of deregulated noncanonical NF-kB activity in B lymphocytes, SMAC-mimetic compounds, which show great promise for the treatment of cancers, could inadvertently sensitize patients toward autoimmune disease or lymphomas 39 . Consequently, the pursuit of this very promising new treatment strategy should proceed cautiously, to better define the therapeutic window and to avoid potential negative immunological side effects.
METHODS
Mice. Traf3 -/-Nfkb2 -/mice have been described previously 13 . To generate Traf3 -/-Map3k14 -/and Traf3 -/-Nfkb1 -/mice, Traf3 +/mice were crossed with either Map3k14 -/-(obtained from Amgen Inc.) or Nfkb1 -/mice (Jackson Laboratories). Targeted disruption of the Traf3, Map3k14, and Nfkb1 alleles has been previously described 11, 40, 41 . All mice were maintained and bred under specific pathogen-free conditions in the University of California, Los Angeles Life Sciences mouse facility, and experiments were conducted within the parameters of our protocol approved by the Animal Research Committee.
cDNA constructs and reagents. Agonistic anti-CD40 antibody was generated from the hybridoma FgK-45. Antibodies to TRAF2 (H249), TRAF3 (M20) and Myc (9E10) were obtained from Santa Cruz Biotechnology. Antibodies to NIK and p100 (p52) were obtained from Cell Signaling Technology. Antibody to rat IAP1 was used to detect endogenous cIAP1 and cIAP2, and has been described previously 42 . M2 (anti-Flag) agarose beads and anti-b-actin were obtained from Sigma. Rabbit TrueBlot horseradish peroxidase anti-rabbit IgG was obtained from eBioscience. The protein G Sepharose beads were obtained from Amersham.
Cell culture and transfections. HEK 293T cells and MEFs were cultured in DMEM (Mediatech Inc) supplemented with 5% FBS, penicillin (100 U/ml) and streptomycin (100 mg/ml). B cells were cultured in RPMI medium 1640 supplemented with 10% FBS, 50 mM b-mercaptoethanol, 100 U/ml penicillin and 100 mg/ml streptomycin (Life Technologies) at 37 1C under 10% CO 2 . BCR-Abl-transformed wild-type and Traf3 -/-B cell lines were generated as described 43 and maintained in RPMI medium supplemented as above. All reconstituted cell lines were generated as described previously 27 . Briefly, HEK 293T cells were transfected with Moloney murine leukemia virus-cA helper construct plus either pBABEpuro alone or the indicated pBABEpuro construct. Traf3 -/and Traf2 -/-MEFs were then infected with the filtered 293T cell supernatants, followed by selection with 2.5 mg/ml of puromycin. Transient transfection of HEK 293T cells was performed using the standard calcium phosphate method. For all transfection experiments, CMV-b-gal was used as a normalization control.
Immunoblotting. Whole cells were lysed in SDS loading buffer (50 mM Tris-Cl, pH 6.8, 1% (vol/vol) b-mercaptoethanol, 2% (wt/vol) SDS, 10% (vol/vol) glycerol, and 0.1% (wt/vol) bromophenol blue). SDS extracts were sonicated for 10 s using the Misonix Sonicator 3000 and then boiled for 5 min. Equal amounts of whole cell lysates were fractionated by 8.5% SDS-PAGE, transferred to polyvinylidene fluoride membranes (Immobilon-P Millipore) and immunoblotted with antibodies according to the manufacturer's recommended instructions. Primary antibodies were detected with either anti-rabbit or anti-mouse antisera conjugated to horseradish peroxidase (Santa Cruz) and were visualized with electrochemiluminescence. For TRAF3 and TRAF2 degradation experiments, cells were stimulated with 5 mg/ml of anti-CD40 in medium alone or in the presence of SMAC mimetic (100 nM).
Immunoprecipitation. Cells were homogenized for 30 min at 4 1C in a modified radioimmune precipitation buffer containing 0.5% (vol/vol) NP-40, 0.1% (wt/vol) sodium deoxycholate and no SDS. Protease inhibitor cocktail (Sigma) was included in all lysates. For pBABE-Flag reconstituted cell lines, 2-5 mg of cell lysates were then incubated with anti-Flag M2 affinity gel for 2 h, followed by treatment with 10 ml of protein G-Sepharose beads (Amersham Biosciences) for another 1 h. For endogenous immunoprecipitation of NIK from primary B cells, A20 cells and BCR-Abl transformed B cells, 5 Â 10 7 cells were pretreated with 5 mg/ml of anti-CD40 or 10 mM MG132 for 4 h. Cell lysates were then incubated with rabbit-IgG (Sigma) or anti-NIK for 4 h, followed by treatment with 10 ml of protein G beads for another 1 h. The immunoprecipitated complexes were separated by SDS-PAGE and blotted with the indicated antibodies. Rabbit TrueBlot horseradish peroxidase-anti-IgG was used as secondary antibody.
siRNA-mediated knockdown. Chemically synthesized siRNA duplexes (see Supplementary Table 1 online for sequences) were purchased from Invitrogen. For each experiment, 1 Â 10 5 MEFs or primary hepatocytes derived from 3-month-old C57BL/6 mice were seeded onto 35-mm wells, and the following morning 500 ng of siRNA duplex was transfected using Lipofectamine RNAiMAX reagent (Invitrogen). Total cell lysates were collected 24 h later for analysis.
B cell purification and stimulation. To obtain pure naive B cells, total splenocytes from 6-to 8-week-old C57BL/6 mice were collected and stained with a biotin-conjugated anti-CD43 (BD Biosciences), followed by streptavidin -conjugated magnetic microbeads (Miltenyi Biotec), and passed through a depletion-type magnetic sorting column (Miltenyi Biotec). Unbound cells were collected as the purified naive B cell sample and analyzed by FACS for B220 and IgM markers. For the B cell survival assay, 2 Â 10 5 B cells were stimulated for 72 h in a flat-bottom 96-well plate with 300 to 3 ng/ml BAFF, 300 to 3 nM SMAC mimetic or LBW242, or medium only, and cell death was measured after staining with propidium iodide and analyzed using a flow cytometer (FACScan; Becton Dickinson). For the B cell proliferation assay, 0.5 Â 10 5 B cells were stimulated for 72 h in a flat-bottom 96-well plate with 300 to 3 ng/ml BAFF or 300 to 3 nM LBW242 and proliferation measured by addition of 0.5 mCi/well [H 3 ]thymidine for the final 24 h. Cellular DNA was then transferred to 96-well Filtermat (Wallac) by automated cell collector and analyzed by scintillation counting.
Measurement of serum corticosterone levels. The corticosterone amount from mouse sera was determined as described previously 13 .
Accession codes. UCSD-Nature Signaling Gateway (http://www.signaling-gate way.org): A002937, A001654, A002309 and A002308.
Note: Supplementary information is available on the Nature Immunology website.
